Phase I/II Randomized Trial of Cord Blood-derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Conditions: Myeloma Interventions: Drug: Fludarabine phosphate; Drug: Cyclophosphamide; Drug: NY-ESO-1 TCR/IL-15 NK Sponsors: M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials